About HPV
HPV refers to a group of more than 200 related viruses commonly causing infections that do not have any symptoms. Among these, more than 40 types of HPV cause highly contagious diseases that are transmitted through direct sexual contact, infecting both male and female genitals. The other types of HPV cause non-genital warts that are not sexually transmitted. Though most HPV infections are harmless and heal on their own, certain high-risk types of genital HPV can be persistent and cause cervical, penile, anal, vaginal, and oropharyngeal cancers. Many individuals undergo regular HPV tests as a preventive measure. HPV tests help detect the viral genetic material in a cell sample taken from the cervix.
Technavio's analysts forecast the global HPV testing market to grow at a CAGR of 16.17% over the period 2014-2019.
Covered in this Report
This report covers the present and future scenarios of the global HPV testing market for the period 2015-2019. To calculate the market size, Technavio uses revenue generated from the sales of HPV testing kits and detection systems. The report includes the segmentation of the market based on the following three regions: the Americas, APAC, and EMEA.
Technavio's report, Global HPV Testing Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Abbott Diagnostics
• Hologic
• Qiagen
• Roche Diagnostics
Other Prominent Vendor
• Arbor Vita
• Becton, Dickinson and Company
• Cepheid
• Delphi Bioscience
• DiaCarta
• Diasorin
• Fujirebio
• Genera Biosystems
• IncellDx
• OralDNA Labs
• Quest Diagnostics
• Seegene
• Trovagene
• Ventana Medical Systems
Market Driver
• Increased Incidence of HPV
• For a full, detailed list, view our report
Market Challenge
• Lack of Public Awareness
• For a full, detailed list, view our report
Market Trend
• Co-testing with HPV and Pap Tests
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 HPV Testing Market in US
06.3.1 Market Size and Forecast
06.4 Five Forces Analysis
07. HPV: An Overview
07.1 HPV Types
07.2 HPV and Cervical Cancer
07.2.1 Incidence and Prevalence
07.2.2 Symptoms
07.2.3 Diagnosis
08. Reimbursement and Coverage: An Overview
09. Geographical Segmentation
09.1 HPV Testing Market in Americas
09.1.1 Market Size and Forecast
09.2 HPV Testing Market in EMEA
09.2.1 Market Size and Forecast
09.3 HPV Testing Market in APAC
09.3.1 Market Size and Forecast
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and Their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and Their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.2 Market Share Analysis 2014
17.3 Other Prominent Vendors
18. Key Vendor Analysis
18.1 Abbott Diagnostics
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Geographical Presence
18.1.4 SWOT Analysis
18.2 Hologic
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Business Segmentation by Revenue 2013
18.2.4 Business Segmentation by Revenue 2012 and 2013
18.2.5 Sales by Geography
18.2.6 Business Strategy
18.2.7 Key Developments
18.2.8 SWOT Analysis
18.3 Qiagen
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Product Segmentation by Revenue 2013
18.3.4 Product Segmentation by Revenue 2012 and 2013
18.3.5 Geographical Segmentation by Revenue 2013
18.3.6 Business Strategy
18.3.7 Recent Developments
18.3.8 SWOT Analysis
18.4 Roche Diagnostics
18.4.1 Key Facts
18.4.2 Business Overview
18.4.3 Business Segmentation by Revenue 2014
18.4.4 Business Segmentation by Revenue 2013 and 2014
18.4.5 Geographical Segmentation by Revenue 2014
18.4.6 Business Strategy
18.4.7 Recent Developments
18.4.8 SWOT Analysis
19. Other Reports in This Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global HPV Testing Market 2014-2019 ($ millions)
Exhibit 3: HPV Testing Market in US 2014-2019 ($ millions)
Exhibit 4: Snapshot: Cervical Cancer
Exhibit 5: Reimbursement Perspectives of Healthcare Entities
Exhibit 6: Segmentation of Global HPV Testing Market by Geography 2014
Exhibit 7: HPV Testing Market in Americas 2014-2019 ($ millions)
Exhibit 8: HPV Testing Market in EMEA 2014-2019 ($ millions)
Exhibit 9: HPV Testing Market in APAC 2014-2019 ($ millions)
Exhibit 10: Segmentation of Global HPV Testing Market by Region 2014-2019
Exhibit 11: Global HPV Testing Market: YoY Growth Rate by Region 2014-2019
Exhibit 12: Abbott Diagnostics: Key Takeaways
Exhibit 13: Hologic: Key Takeaways
Exhibit 14: Qiagen: Key Takeaways
Exhibit 15: Roche Diagnostics: Key Takeaways
Exhibit 16: Abbott Diagnostics: Geographical Presence
Exhibit 17: Hologic: Revenue Segmentation 2013
Exhibit 18: Revenue Comparison FY2012 and FY2013 ($ millions)
Exhibit 19: Hologic: Sales by Geography 2013
Exhibit 20: Qiagen: Product Segmentation by Revenue 2013
Exhibit 21: Qiagen: Product Segmentation by Revenue 2012 and 2013 ($ millions)
Exhibit 22: Qiagen: Geographical Segmentation by Revenue 2013
Exhibit 23: Roche Diagnostics: Business Segmentation by Revenue 2014
Exhibit 24: Roche Diagnostics: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 25: Roche Diagnostics: Geographical Segmentation by Revenue 2014
